What are the eligibility criteria and dosing schedule for rechallenging a male patient with metastatic castration‑resistant prostate cancer who previously received Lu‑177‑PSMA‑617, achieved at least a partial biochemical or radiographic response, and experienced only mild‑to‑moderate reversible toxicity?

Lu-177 PSMA Radioligand Rechallenge Therapy

Rechallenge with Lu-177-PSMA-617 is feasible and effective in mCRPC patients who previously responded to initial therapy, with the standard regimen of 7.4 GBq every 6 weeks for up to 6 cycles, provided they maintain PSMA-positive disease and acceptable organ function.

Eligibility Criteria for Rechallenge

Essential Requirements

PSMA Expression Status:

• Confirm PSMA-positive disease on repeat imaging with Ga-68 PSMA-11, F-18 piflufolastat, or F-18 flotufolastat PET/CT 1
• PSMA positivity must be documented before each rechallenge course

Prior Response Documentation:

• Achieved at least partial biochemical response (PSA decline) or radiographic response to initial Lu-177-PSMA-617 therapy 2
• Disease control rate (stable disease or better) during initial treatment 3

Toxicity Profile from Initial Therapy:

• Only mild-to-moderate (Grade 1-2) reversible toxicity during initial treatment 2
• No Grade 4 adverse events from prior therapy 2
• Permanent Grade 3 toxicity is not an absolute contraindication but requires careful consideration 2

Organ Function Requirements:

• Check blood counts, renal function, and hepatic function before each cycle 1
• Adequate bone marrow reserve (specific thresholds not defined in guidelines but extrapolated from trial data)
• Acceptable renal function for radioprotection

Timing Considerations

Progression Interval:

• Median time to rechallenge in published series: 6 months (range 2-26 months) after initial therapy 2
• No minimum or maximum interval specified in guidelines
• Earlier rechallenge may be considered if symptomatic progression occurs

Dosing Schedule for Rechallenge

Standard Regimen

• Dose: 7.4 GBq per cycle 4
• Frequency: Every 6 weeks 4
• Number of cycles: Up to 6 cycles 4
• Concurrent therapy: Continue androgen deprivation therapy 4

Monitoring During Rechallenge

• Blood counts before each cycle 1
• Renal function before each cycle 1
• Hepatic function before each cycle 1
• Radioprotection precautions per national/local regulations 1

Expected Outcomes

Efficacy Data from Rechallenge Studies

Biochemical Response:

• 75-90% of patients show benefit (response or stable disease) from the first 4 rechallenge cycles 2
• PSA decline >50% achieved in significant proportion of selected patients 3
• Renewed PSA reductions observed with rechallenge 5

Survival Outcomes:

• Median overall survival from first rechallenge cycle: 12 months 2
• Median overall survival from initial baseline therapy: 25 months in rechallenged patients vs. 9 months in those receiving only baseline therapy (p<0.001) 2
• Patients with PSA decrease after first rechallenge cycle survived median 19 months vs. 6 months for non-responders 2

Symptomatic Response:

• Sustained symptomatic improvement and pain relief 5
• Favorable quality-of-life performance 3

Safety Profile of Rechallenge

Hematologic Toxicity

• Grade 3 toxicity: Occurred in 27% of rechallenged patients 2
• Specific Grade 3 events: Leukopenia (n=2), neutropenia (n=1), anemia (n=4), thrombocytopenia (n=4) 2
• Grade 4 toxicity: None reported in rechallenge series 2
• Irreversible adverse events: Occurred in 70% but mostly mild/moderate (Grade 1-2 in 90% of these) 2

Non-Hematologic Toxicity

• Elevated renal parameters (Grade 3) in 1 patient 2
• No grade III-IV renal toxicities in recent case series 5
• Generally mild and manageable toxicities compared to chemotherapy alternatives 3

Cumulative Toxicity Considerations

• Hematotoxicity, particularly anemia and thrombocytopenia, is the most significant concern with extended/rechallenge therapy 6
• Cumulative irradiation necessitates careful monitoring of hematologic and renal function 6

Clinical Decision Algorithm

Step 1: Confirm Eligibility

1. Document PSMA-positive disease on repeat PET imaging
2. Verify prior response (biochemical or radiographic) to initial Lu-177-PSMA-617
3. Confirm only mild-moderate toxicity from initial therapy
4. Check baseline organ function (CBC, renal, hepatic)

Step 2: Assess Disease Characteristics

• Progressive disease after initial benefit (median 6-9 months post-treatment) 7
• PSMA-avid lesions on imaging
• Castration-resistant status maintained

Step 3: Implement Rechallenge

• Administer 7.4 GBq every 6 weeks
• Plan for up to 6 cycles
• Monitor organ function before each cycle
• Continue ADT throughout

Step 4: Response Assessment

• PSA response after first rechallenge cycle is prognostic 2
• Patients with PSA decline have significantly better survival
• Consider discontinuation if PSA rises after first rechallenge cycle

Important Caveats and Pitfalls

Patient Selection

• Critical pitfall: Rechallenging patients who had Grade 3-4 toxicity during initial therapy increases risk of severe adverse events
• Avoid: Rechallenge in patients with PSMA-negative progression (indicates resistance mechanism)
• Consider: Multidisciplinary discussion before rechallenge, particularly regarding alternative therapies 1

Alternative Considerations

The 2025 ASCO guideline 4 positions Lu-177-PSMA-617 for PSMA-positive mCRPC patients post-ARPI and docetaxel. For patients progressing after initial Lu-177-PSMA-617, alternative options include:

• Cabazitaxel (if not previously used)
• Alpha-based PRLT with Ac-225-PSMA-617 (emerging data shows favorable outcomes) 3
• Clinical trials

Regulatory Context

• FDA approval is for up to 6 cycles in the initial treatment setting
• Rechallenge represents off-label use requiring informed consent
• International regulatory differences exist regarding extended/rechallenge therapy 6

Re-Rechallenge Possibility

• Multiple rounds of rechallenge (re-rechallenge) have been reported as safe and effective 7
• Each subsequent rechallenge requires the same eligibility assessment
• Cumulative toxicity monitoring becomes increasingly important

Emerging Evidence

The PSMAfore trial 4 has expanded indications to taxane-naïve patients, but rechallenge data specifically in this population is not yet available. The NCCN 2025 and EAU 2025 guidelines acknowledge this expansion, though rechallenge protocols remain based on post-taxane populations 8.

The evidence strongly supports rechallenge therapy as a viable option that extends survival and maintains quality of life with acceptable toxicity in appropriately selected patients who previously benefited from Lu-177-PSMA-617.